科技缔造光明视界 ——高视医疗战略升级，攀登眼科医疗器械新高峰 本次专访中，刘新伟先生多次提及了"中国本土眼科医疗器械引领者""眼科医 疗器械整体解决方案专家"、"经销业务与自有产品业务并重及协同发展"、"自 有产品业务覆盖白内障诊疗、眼底疾病诊疗及近视防控诊疗"、"4+2 基地布 局，搭建中国和欧洲两地覆盖研发生产的双供应链体系"、"国产化、技术引 进、并购、产品生命周期重启、自主研发"、"创新引领国际化业务拓展"等， 字里行间体现着高视医疗二十余年的战略延续与革新。在这新的历史变革期， 高视医疗战略升级有望引领公司在眼科医疗器械攀登新的高峰，并为行业发展 带来新的启发与思路。 一、 深化战略、高效落地，高视医疗已成为中国本土眼科医疗器械引领企业 企业的战略、使命、愿景如何随着企业的发展、行业的竞争以及商业环境 的变化进行优化升级，使得企业稳健运营、持续发展并实现业绩的增长是一个 经久不衰的话题。近几年，国际商业环境出现了新的变化，更需要企业因势利 导，在时代变革中寻找正确的前进方向。 中国有一批本土代表性企业，发展初期主要是代理销售国外的产品，一步 步建立营销网络，积累对行业和市场的洞见，并探索出符合市场 ...

Core Viewpoint - The Chinese medical industry has entered a new development stage influenced by multiple factors such as international expansion, centralized procurement mechanisms, and geopolitical dynamics. The focus has shifted from whether companies can go international to whether they possess the capability for long-term participation in global competition [2]. Group 1: Multi-Dimensional Collaborative Layout Capability - In the global high-end medical device sector, especially in complex disease and high-risk treatment scenarios, competitive advantage relies on systematic collaboration across different treatment stages and technological pathways rather than on single-point advantages [3]. - MicroPort Medical's business structure exemplifies strong representation in this dimension, covering multiple high-risk and high-tech core tracks, forming a business combination across cardiovascular, neurological, orthopedic, and surgical robotics fields [3]. Group 2: Clinical Closed-Loop Capability - The concept of "clinical closed-loop" in high-end medical devices refers to the ability to continuously and stably deliver medical solutions into real clinical systems, encompassing a complete chain from technological innovation to long-term follow-up [6]. - MicroPort Medical demonstrates distinctive features in this area, including a focus on Class III high-risk devices, a high density of "first/only" level technological innovations across multiple tracks, and a clinical technology foundation that integrates multiple pathways [7][8]. Group 3: Global Operational Capability - The true challenge of globalization lies not in the number of countries entered but in the ability to operate continuously under different regulatory systems, clinical environments, and commercial logics, forming long-term synergies across R&D, registration, supply chain, academia, and market [11]. - MicroPort Medical has established a multi-regional collaborative operational system, integrating domestic and overseas markets into a cohesive global framework, leveraging its product and clinical foundation in China to accelerate market entry for new technologies and products [12]. Group 4: Academic-Driven International Pathway - In mature markets like Europe, clinical and academic evidence is crucial for entering mainstream medical systems. MicroPort Medical has built academic recognition through high-quality clinical data and multi-center studies, maintaining close collaborations with key opinion leaders (KOLs) [16]. - The company's products have completed international multi-center clinical studies, establishing a strong academic influence and clinical trust in overseas markets [16][18]. Group 5: Industry Observation - As the industry evolves, global competition is increasingly focused on integrated capabilities encompassing technology R&D, clinical transformation, and data accumulation, raising higher demands for organizational systems and cross-field collaboration [21]. - MicroPort Medical's practices provide a valuable reference for how Chinese medical device companies can establish long-term competitiveness in the global high-end system [21].

Core Insights - The acquisition of Shenzhen Huatai Medical Equipment Co., Ltd. by Mindray Medical International Limited marks a significant milestone as the first "A-controlled A" merger on the STAR Market, symbolizing a pivotal moment for the consolidation of the medical device industry in China [2] - The integration process has been efficient, taking only three months from announcement to completion, setting a benchmark for large-scale medical mergers [2] - The focus post-acquisition has been on collaboration in research and development, marketing, business expansion, and operations, particularly in the electrophysiology sector, which is deemed crucial for future growth [2] Integration and Collaboration - Mindray Medical has previously executed nearly 20 investment and acquisition projects, with a total transaction amount exceeding 10 billion, laying a solid foundation for enhancing core technology and expanding global business [3] - The integration strategy emphasizes maintaining independent operational decision-making for both companies while fostering complementary collaboration rather than complete absorption [4] - A dedicated team of over 200 personnel was deployed by Mindray Medical in the first year post-acquisition to ensure effective collaboration, representing nearly 10% of Huatai Medical's total workforce [3] Research and Development - The medical device industry is increasingly relying on external acquisitions for growth, driven by the need for scale and innovation [6] - Huatai Medical's R&D investment reached 98 million, with a research expense ratio of 14.98%, reflecting a year-on-year increase of 1.8 percentage points [6] - The electrophysiology segment is identified as a key growth driver, with over 2,000 pulse field ablation surgeries completed by the third quarter of 2025, and an expected annual total exceeding 5,000 surgeries [7] Global Expansion Strategy - The global expansion of medical device companies is being accelerated through mergers, overseas factories, and industrial funds [8] - Successful international business development requires thorough pre-merger research on legal, regulatory, and operational aspects of target markets [8] - Huatai Medical is focused on establishing a systematic "going global" framework to meet the increasing demands of international investors regarding governance, compliance, and operational standards [9]

Financial Data and Key Metrics Changes - The core business is expected to grow between 4%-7%, which aligns with the weighted average market growth rate of 4%-6% [6][8] - The company anticipates a short-term headwind due to three specific products not achieving the expected market adoption rate in 2026, impacting overall performance [7][15] - The stock is considered undervalued, with the fundamentals and core business remaining strong despite the current challenges [23][51] Business Line Data and Key Metrics Changes - The company focuses on fast-growing markets such as electrophysiology, neurovascular, structural heart, and neuromodulation, with 80% of the product development sales pipeline concentrated in these areas [4][5] - The electrophysiology portfolio has performed well over the past four to five years, although two specific products are facing adoption challenges [25][15] - The overall portfolio, excluding the impacted products, is still expected to grow at a strong double-digit rate [28] Market Data and Key Metrics Changes - The medical device market is experiencing significant innovation, particularly in electrophysiology and structural heart segments, which are expected to drive future growth [25][29] - The company has a global manufacturing footprint, which allows it to remain competitive despite potential tariff impacts [50][51] Company Strategy and Development Direction - The company aims to be the most innovative Contract Development and Manufacturing Organization (CDMO) in the world, focusing on building critical engineering and manufacturing capabilities [10][11] - The strategy includes targeted acquisitions to enhance capabilities and a strong emphasis on organic growth through innovative product launches [4][55] - The company is committed to maintaining operational efficiency through its Integer Production System, which focuses on lean manufacturing practices [39][40] Management's Comments on Operating Environment and Future Outlook - Management views the current challenges as a short-term air pocket, expecting to return to growth in the second half of 2026 and above-market growth in 2027 [8][61] - The company is confident in its strong pipeline and the ability to weather the current market pressures due to its diversified portfolio [17][63] - Management emphasizes the importance of customer relationships and market feedback in navigating product performance and demand [21][22] Other Important Information - A $200 million share repurchase program has been authorized, reflecting the board's confidence in the company's fundamentals and growth strategy [11][12] - The company has not previously engaged in share repurchase programs, indicating a strategic shift in capital allocation [12] Q&A Session Summary Question: What are the expectations for the company's growth in the coming years? - Management expects to return to market growth in the second half of 2026 and achieve above-market growth in 2027, driven by new product launches and a strong core business [60][61] Question: How does the company plan to manage costs during the current air pocket? - The company will focus on generating gross margin expansion through lean manufacturing and will be disciplined in managing fixed costs during this period [39][40] Question: What is the company's approach to acquisitions? - The company is focused on tuck-in acquisitions that enhance critical capabilities rather than transformative acquisitions, which were more common in the past [55]

Financial Data and Key Metrics Changes - The core business is expected to grow between 4% to 7% in 2026, which aligns with the weighted average market growth rate of 4% to 6% [6] - The company anticipates a short-term headwind due to three specific products that are not achieving the expected market adoption rates in 2026, impacting growth [6][7] - The stock is considered undervalued by management, reflecting strong fundamentals and financial strength [10][20] Business Line Data and Key Metrics Changes - The product development sales pipeline is approximately 80% focused on the fastest-growing markets, indicating a strong growth trajectory [5] - The electrophysiology portfolio has been performing well, with significant growth over the past four to five years, despite current headwinds [22][25] - The company is diversifying its portfolio, with no single program representing more than a few percentage points of total revenues, which mitigates risk [15] Market Data and Key Metrics Changes - The medical device market is experiencing a phase of multiple new product iterations, indicating a dynamic environment for innovation [21] - The company is well-positioned in the medtech ecosystem, partnering with both large and emerging companies [3] Company Strategy and Development Direction - The strategy focuses on building differentiated capabilities through organic growth and targeted acquisitions to enhance product offerings [4] - The company aims to be the most innovative contract development and manufacturing organization (CDMO) in the world, emphasizing engineering expertise and manufacturing efficiency [9][10] - Future growth is expected to be driven by new product launches in the second half of 2026 and into 2027, with a strong pipeline of innovative therapies [39][55] Management's Comments on Operating Environment and Future Outlook - Management views the current challenges as a short-term air pocket, expecting a return to growth in the second half of 2026 and above-market growth in 2027 [8][20] - The company is committed to maintaining operational efficiency and managing costs during this period, focusing on areas that will drive future growth [36] - Management is optimistic about the strength of the pipeline and the potential for market recovery, emphasizing the importance of execution and quality [9][20] Other Important Information - The company has initiated a $200 million share repurchase program, reflecting confidence in its financial strength and strategy [10] - The global manufacturing footprint is designed to mitigate risks associated with tariffs and ensure cost competitiveness [43][47] Q&A Session Summary Question: What is the outlook for the company's growth in 2026 and beyond? - Management expects to return to market growth in the second half of 2026 and achieve above-market growth in 2027, driven by new product launches and a strong pipeline [55][56] Question: How does the company manage costs during the current air pocket? - The company plans to focus on manufacturing efficiencies and be disciplined in managing fixed costs during this period [36] Question: What is the company's strategy regarding acquisitions? - The company is focused on tuck-in acquisitions to build critical capabilities rather than transformative acquisitions [49]

Group 1 - The core viewpoint of the news is that Shenzhen Huatai Medical has seen a stock price increase of 5.11%, reaching 289.48 CNY per share, with a total market capitalization of 40.821 billion CNY [1] - Shenzhen Huatai Medical specializes in the research, production, and sales of electrophysiology and vascular interventional medical devices, with its main business revenue composition being: coronary access 53.90%, electrophysiology 20.23%, peripheral intervention 17.51%, OEM 6.01%, non-vascular intervention 1.88%, and others 0.46% [1] Group 2 - According to data from the top ten holdings of funds, one fund under Jianxin Fund has a significant position in Huatai Medical, specifically the Jianxin CSI All-Share Medical Equipment and Services ETF (159891), which reduced its holdings by 400 shares in the third quarter, now holding 12,400 shares, accounting for 2.88% of the fund's net value [2] - The Jianxin CSI All-Share Medical Equipment and Services ETF (159891) has a current scale of 137 million CNY, with a year-to-date return of 6.28%, ranking 3906 out of 4216 in its category, and a one-year return of 1.71%, ranking 3744 out of 3901 [2] Group 3 - The fund manager of Jianxin CSI All-Share Medical Equipment and Services ETF (159891) is Gong Jiajia, who has been in the position for 6 years and 259 days, with the fund's total asset size at 1.056 billion CNY [3] - During Gong Jiajia's tenure, the best fund return was 44.21%, while the worst return was -53.64% [3]

Core Insights - HuiTai Medical reported a revenue of 1.867 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 22.47% [1] - The net profit attributable to shareholders was 623 million yuan, with an 18.02% increase year-on-year [1] - The basic earnings per share stood at 4.42 yuan [2] Financial Performance - The gross profit margin for the first three quarters was 73.19%, up by 0.50 percentage points year-on-year [2] - The net profit margin was 32.92%, down by 1.31 percentage points compared to the same period last year [2] - In Q3 2025, the gross profit margin was 72.60%, showing a slight year-on-year increase but a decrease of 1.28 percentage points quarter-on-quarter [2] - The net profit margin for Q3 was 29.97%, down 5.15 percentage points year-on-year and 6.79 percentage points quarter-on-quarter [2] Expense Analysis - Total operating expenses for Q3 2025 were 667 million yuan, an increase of 131 million yuan year-on-year [2] - The expense ratio was 35.71%, up by 0.58 percentage points from the previous year [2] - Sales expenses increased by 23.51%, management expenses rose by 27.12%, and R&D expenses grew by 25.78%, while financial expenses decreased by 58.42% [2] Shareholder Information - As of the end of Q3 2025, the total number of shareholders was 5,690, an increase of 1,183 or 26.25% from the end of the previous half [3] - The average market value per shareholder decreased from 9.2925 million yuan to 7.8494 million yuan, a decline of 15.53% [3] Company Overview - Shenzhen HuiTai Medical Equipment Co., Ltd. specializes in the research, production, and sales of electrophysiology and vascular interventional medical devices [3] - The revenue composition includes 53.90% from coronary access, 20.23% from electrophysiology, 17.51% from peripheral intervention, 6.01% from OEM, 1.88% from non-vascular intervention, and 0.46% from other sources [3] - The company is categorized under the pharmaceutical and biological industry, specifically in medical devices and consumables [3]

Group 1 - The global medical device market is expected to reach $862.6 billion by 2030, with a CAGR of 5% from 2025E to 2030E, driven by factors such as aging population, rising chronic disease prevalence, medical technology advancements, policy support, and improved healthcare systems [1] - In 2025, the market share distribution is projected as follows: North America (32%), Europe (25%), China (8%), Asia-Pacific (19%), Latin America (11%), and Middle East & Africa (5%) [1] - The market segments are expected to be distributed as follows: high-value consumables (32%), low-value consumables (12%), medical imaging equipment (12%), in vitro diagnostics (13%), and others (31%) [1] Group 2 - The valuation of leading global medical device companies shows significant differentiation, with high-growth segments enjoying P/E ratios between 31-57x for 2025E, while mature platform companies typically have P/E ratios of 13-18x for 2025E [2] - The core reason for valuation differentiation is the market's varying expectations for future growth and the technological barriers/sustainable advantages within specific segments [2] Group 3 - Eight key segments identified for potential growth include electrophysiology, renal denervation (RDN), complex vascular interventions, structural heart, neuroscience, surgical robotics, endoscopy, and glucose management [3] - These segments are expected to experience upgrades in procedures or product iterations, or may open up untapped markets through new technologies, leading to significant commercialization opportunities [3] - High-growth leaders in these segments may enjoy long-term premium valuations due to their high barriers to entry, while traditional giants may boost performance and valuation through significant product launches [3]

Financial Data and Key Metrics Changes - Sales for Q3 2025 totaled $468 million, reflecting an 8% growth on a reported basis and 7% growth organically [13][9] - Adjusted operating income increased by 14% year over year, with adjusted EPS growing 25% to $1.79 [15][9] - Year-to-date sales are up 9%, adjusted operating income is up 14%, and adjusted EPS is up 20% [30] Business Line Data and Key Metrics Changes - Cardio and vascular sales increased by 15% in Q3 2025, driven by new product ramps in electrophysiology and strong demand in neurovascular [15] - Cardiac rhythm management solutions sales increased by 2% year over year, with expectations for mid-teens growth for the full year 2025 [16][17] - Neuromodulation sales growth was impacted by lower demand from select emerging customers, with expectations for low single-digit growth for the full year 2025 [17] Market Data and Key Metrics Changes - The market adoption of new electrophysiology products has been slower than anticipated, leading to a forecast reduction for 2026 [11][12] - The company expects a 3% to 4% headwind to total sales in 2026 due to the decline in three new products [11][12] - The overall market in which the company competes is growing at a steady mid-single digit rate [29] Company Strategy and Development Direction - The company remains confident in its long-term growth strategy, focusing on early design wins in high-growth markets [12][29] - A strong product development pipeline is expected to drive above-market growth in 2027 [28][29] - The company plans to continue its acquisition strategy while maintaining a leverage ratio within the targeted range of 2.5 to 3.5 times [29] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a reduction in the financial outlook due to unexpected changes in customer forecasts for new products [5][9] - Despite the challenges, management expressed confidence in the company's strategy and operational execution [6][12] - The company anticipates a recovery to market growth in the second half of 2026 as new product headwinds moderate [11][12] Other Important Information - The adjusted effective tax rate for Q3 2025 was 16.3%, down from 17.2% in the prior year, with expectations for the full year to be between 17% and 18% [18] - Free cash flow for Q3 was $46 million, flat compared to the prior year, with net total debt decreasing to $1,158 million [19][24] Q&A Session Summary Question: Can you elaborate on the organic growth of the rest of the portfolio? - Management indicated that without new product introductions, the rest of the portfolio is expected to grow at market rates, which is lower than the typical 6% to 8% growth [32][33] Question: What are the expected headwinds in the cardio and vascular items? - The headwinds are related to two electrophysiology products with slower market adoption than anticipated, not due to loss of market share [34][36] Question: How confident is the company in returning to market growth by Q4 2026? - Management expressed confidence due to steady backlog and customer forecasts, despite the unusual simultaneous changes in multiple products [38][39] Question: What changes will be made to the forecasting process? - The company is reflecting on its forecasting processes but maintains that its algorithm for risk-adjusting forecasts remains unchanged [90][92]

Financial Data and Key Metrics Changes - Sales for Q3 2025 totaled $468 million, reflecting an 8% growth on a reported basis and 7% growth organically [13][9] - Adjusted operating income increased by 14% year-over-year, with adjusted EPS growing by 25% to $1.79 [15][9] - For the full year 2025, the company expects sales growth between 7% and 8%, with adjusted operating income growth between 12% and 14% [20][10] Business Line Data and Key Metrics Changes - Cardio and vascular sales increased by 15% in Q3 2025, driven by new product ramps and strong demand in neurovascular [15] - Cardiac rhythm management solutions sales increased by 18% year-over-year, but growth is expected to decelerate in Q4 2025 due to anticipated declines in new products [16][10] - Neuromodulation sales increased by 2% in Q3 2025, with expectations for low single-digit growth for the full year [17] Market Data and Key Metrics Changes - The company anticipates a 3% to 4% headwind to total sales in 2026 due to slower market adoption of three new products [11][25] - The portable medical exit is expected to contribute a 2% headwind to total sales in 2026 [11][25] - The overall market in which the company competes is growing at a steady mid-single digit rate [29] Company Strategy and Development Direction - The company remains confident in its long-term growth strategy, focusing on early design wins in high-growth markets [12][29] - A strong product development pipeline is expected to drive above-market growth in 2027 [28][29] - The company plans to continue its acquisition strategy while maintaining a leverage ratio within the targeted range of 2.5 to 3.5x [29] Management's Comments on Operating Environment and Future Outlook - Management acknowledged recent customer forecast changes impacting the financial outlook but expressed confidence in the long-term strategy [5][10] - The company expects a recovery to market growth in the second half of 2026 as new product headwinds moderate [11][12] - Management highlighted the unusual nature of simultaneous forecast changes from multiple customers as a significant factor affecting the outlook [59] Other Important Information - The adjusted effective tax rate for Q3 2025 was 16.3%, down from 17.2% in the prior year, with expectations for the full year to be within the range of 17%-18% [18] - The company generated $66 million of cash flow from operations in Q3 2025, with free cash flow remaining flat at $46 million [19] Q&A Session Summary Question: Can you elaborate on the organic growth of the rest of the portfolio? - Management indicated that without new product introductions, the rest of the portfolio is expected to grow at market rates, which is lower than the typical 6%-8% growth [32][33] Question: What are the expected headwinds in the cardio and vascular items? - The headwinds are related to two electrophysiology products with slower market adoption than anticipated, not due to loss of market share [34][36] Question: How confident is the company in returning to market growth by Q4 2026? - Management expressed confidence due to steady backlog and customer forecasts, despite the unusual simultaneous changes in multiple products [38][39] Question: What is the nature of the changes in the electrophysiology products? - The changes are due to customers adjusting their forecasts based on lower-than-expected market adoption rates [42][46] Question: Is the decline in neuromodulation similar to electrophysiology? - Yes, the decline is attributed to slower market adoption from emerging customers, although the overall book of business is still growing [52][57] Question: How does the company plan to manage costs in 2026? - The company will focus on operational efficiencies and disciplined cost management to navigate the expected headwinds [85][86]